Earnings Summary

Biontech Se’s revenue fell -65.43% since last year same period to $1479Mn in the Q4 2023. On a quarterly growth basis, Biontech Se has generated 65.2% jump in its revenue since last 3-months.

Biontech Se’s net profit fell -79.91% since last year same period to $457.9Mn in the Q4 2023. On a quarterly growth basis, Biontech Se has generated 185.12% jump in its net profits since last 3-months.

Biontech Se’s net profit margin fell -41.87% since last year same period to 30.96% in the Q4 2023. On a quarterly growth basis, Biontech Se has generated 72.59% jump in its net profit margins since last 3-months.

Biontech Se’s price-to-earnings ratio after this Q4 2023 earnings stands at 21.54.

Biontech Se’s earning per share (EPS) estimates for the current quarter stand at -1.16 - a -147.93% fall from last quarter’s estimates.

Biontech Se’s earning per share (EPS) estimates for the current year stand at -1.16.

Biontech Se’s earning per share (EPS) fell -79.48% since last year same period to 1.9 in the Q4 2023. This indicates that the Biontech Se has generated -79.48% annual rate of fall in its earning per share (EPS) in the last 4 quarters.

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Biontech Se’s return on assets (ROA) stands at 0.03.

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Biontech Se’s return on equity (ROE) stands at 0.05.